CA2642826C - Mapc treatment of brain injuries and diseases - Google Patents

Mapc treatment of brain injuries and diseases Download PDF

Info

Publication number
CA2642826C
CA2642826C CA2642826A CA2642826A CA2642826C CA 2642826 C CA2642826 C CA 2642826C CA 2642826 A CA2642826 A CA 2642826A CA 2642826 A CA2642826 A CA 2642826A CA 2642826 C CA2642826 C CA 2642826C
Authority
CA
Canada
Prior art keywords
cells
brain injury
subject
use according
mapcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2642826A
Other languages
English (en)
French (fr)
Other versions
CA2642826A1 (en
Inventor
Robert W. Mays
Robert J. Deans
David C. Hess
James E. Carroll
Cesar V. Borlongan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABT Holding Co
Augusta University Research Institute Inc
Original Assignee
Athersys Inc
Augusta University Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc, Augusta University Research Institute Inc filed Critical Athersys Inc
Priority to CA3028321A priority Critical patent/CA3028321C/en
Publication of CA2642826A1 publication Critical patent/CA2642826A1/en
Application granted granted Critical
Publication of CA2642826C publication Critical patent/CA2642826C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/54Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0607Non-embryonic pluripotent stem cells, e.g. MASC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2642826A 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases Active CA2642826C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3028321A CA3028321C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76095106P 2006-01-23 2006-01-23
US60/760,951 2006-01-23
PCT/US2007/001746 WO2007087292A2 (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3028321A Division CA3028321C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Publications (2)

Publication Number Publication Date
CA2642826A1 CA2642826A1 (en) 2007-08-02
CA2642826C true CA2642826C (en) 2019-01-08

Family

ID=40280746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2642826A Active CA2642826C (en) 2006-01-23 2007-01-23 Mapc treatment of brain injuries and diseases

Country Status (9)

Country Link
EP (1) EP1981515B1 (https=)
JP (1) JP5432527B2 (https=)
AU (1) AU2007208367B2 (https=)
CA (1) CA2642826C (https=)
DK (1) DK1981515T3 (https=)
ES (1) ES2420957T3 (https=)
NZ (1) NZ570614A (https=)
PL (1) PL1981515T3 (https=)
WO (1) WO2007087292A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
CA2734237C (en) * 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
SG10201807935SA (en) * 2008-09-04 2018-10-30 Abt Holding Co Use of stem cells to prevent neuronal dieback
SG178064A1 (en) * 2009-07-21 2012-03-29 Abt Holding Co Use of stem cells to reduce leukocyte extravasation
WO2011106521A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of macrophage activation
WO2011106476A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
ES2707579T3 (es) 2011-06-01 2019-04-04 Celularity Inc Tratamiento del dolor usando citoblastos placentarios
KR20160098244A (ko) * 2013-11-15 2016-08-18 안트로제네시스 코포레이션 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도
CN105331583B (zh) * 2015-12-08 2019-01-29 广州医科大学附属第三医院 一种促进人诱导多能干细胞向神经元诱导分化的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7838289B2 (en) 2001-02-14 2010-11-23 Abt Holding Company Assay utilizing multipotent adult stem cells
US9969980B2 (en) * 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
EP1471970A4 (en) * 2002-01-14 2006-08-02 Univ Illinois NOVEL MULTIPOTENT STEM CELLS OF MAMMALIAN ORIGIN, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION OF SAID CELLS
WO2004099395A2 (en) * 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells

Also Published As

Publication number Publication date
AU2007208367B2 (en) 2013-05-16
DK1981515T3 (da) 2013-07-22
WO2007087292A3 (en) 2007-11-22
JP5432527B2 (ja) 2014-03-05
EP1981515A2 (en) 2008-10-22
AU2007208367A1 (en) 2007-08-02
JP2009523846A (ja) 2009-06-25
ES2420957T3 (es) 2013-08-28
PL1981515T3 (pl) 2014-02-28
NZ570614A (en) 2012-07-27
EP1981515B1 (en) 2013-04-24
WO2007087292A2 (en) 2007-08-02
CA2642826A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
US20210299185A1 (en) Mapc treatment of brain injuries and diseases
CA2642826C (en) Mapc treatment of brain injuries and diseases
US10117900B2 (en) MAPC treatment of brain injuries and diseases
US20220118026A1 (en) Mapc treatment of brain injuries and diseases
HK1224562A1 (en) Mapc treatment of brain injuries and diseases
HK1130695A (en) Mapc treatment of brain injuries and diseases
HK1130694A (en) Mapc therapeutics without adjunctive immunosuppressive treatment

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260212